MS006

MS006 is a preclinical-stage monoclonal antibody developed by Medimscience that targets MT006, a proprietary macrophage-related protein. The therapeutic candidate is being investigated for the treatment of various solid tumors. Its mechanism of action involves binding to MT006 to modulate the function of tumor-associated macrophages (TAMs) within the tumor microenvironment. By targeting this proprietary macrophage-related protein, MS006 aims to reprogram the immunosuppressive microenvironment into an immunostimulatory one, thereby enhancing the overall anti-tumor immune response. MS006 is part of Medimscience's pipeline focused on innovative innate immunity targets and the modulation of the tumor microenvironment.